Zylox-Tonbridge Medical Technology (2190) Fundamentals 2026 — P/E 21.9x, Revenue Analysis | SniperIQ
Zylox-Tonbridge Medical Technology (2190) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$6.0B, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zylox-Tonbridge Medical Technology's market cap?
Zylox-Tonbridge Medical Technology (2190) has a market capitalization of approximately HK$6.0B, trading at HK
What is Zylox-Tonbridge Medical Technology's P/E ratio?
Zylox-Tonbridge Medical Technology's trailing twelve-month P/E ratio is 21.9x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zylox-Tonbridge Medical Technology?
Zylox-Tonbridge Medical Technology runs a net profit margin of 22.9%, a gross margin of 72.1%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zylox-Tonbridge Medical Technology generate?
Zylox-Tonbridge Medical Technology reported revenue of ¥1.1B for fiscal year 2025, with net income of ¥244M and earnings per share (EPS) of 0.76. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zylox-Tonbridge Medical Technology pay a dividend?
Zylox-Tonbridge Medical Technology offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zylox-Tonbridge Medical Technology financially healthy?
Zylox-Tonbridge Medical Technology carries a debt-to-equity ratio of 0.02x and a current ratio of 5.98x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zylox-Tonbridge Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zylox-Tonbridge Medical Technology (2190) the key facts are: market cap HK$6.0B, P/E 21.9x, revenue ¥1.1B, 52-week range 17.1-28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zylox-Tonbridge Medical Technology's full fundamentals live
Get Zylox-Tonbridge Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.